Peptides span a surprisingly wide range of biological functions, from growth hormone signalling and tissue repair to metabolic regulation and melanocortin activity. Rather than treating each compound as an isolated curiosity, the most productive approach is to group peptides by their mechanism of action, then evaluate each class on its own terms for research relevance, safety flags, and supply quality. That framework is exactly what we set out to build here.
Drawing on a detailed conversation with Dr Kyle Gillette, a physician who routinely works across endocrinology, obesity medicine, and peptide pharmacology, we walk through the main peptide classes, where SARMs sit in relation to them, and what UK-based research buyers should look for when sourcing compounds for laboratory investigation.
How Peptides Are Best Understood By Class
Why Classification Matters More Than Hype
Peptides are not a single product category. They are a structural format, short chains of amino acids, that can act on entirely different receptor systems. Lumping BPC-157 in with semaglutide makes about as much sense as filing aspirin next to insulin because both come in tablet form.
When we classify peptides by their receptor target or signalling pathway, the picture sharpens. Risk profiles become clearer. Research questions become more precise. And sourcing decisions become easier to justify, because each class has its own purity benchmarks and stability requirements.
The Main Groups Covered In This Guide
The categories we focus on here mirror the framework Dr Gillette uses in clinical practice:
- GHRPs and GHRH analogues (growth hormone signalling)
- VEGF-related compounds such as BPC-157 (angiogenesis and tissue repair)
- Growth agonists including TB-500 and GHK-Cu (regenerative signalling)
- Melanocortin receptor agonists (melanotan variants, PT-141, setmelanotide)
- Amylin analogues (metabolic and pancreatic research)
- GLP-1 receptor agonists (incretin pathways)
- SARMs (selective androgen receptor modulators, a related but distinct compound class)
Each group carries different research priorities and different safety considerations.
Research-Only Context And UK Supply Considerations
None of the compounds discussed here should be treated as consumer supplements or self-administered therapies. In the UK market, research-grade peptides and SARMs are sold strictly for laboratory investigation. Responsible suppliers make this distinction explicit in labelling, documentation, and terms of sale.
For UK research buyers, the practical question is not just which compound to study, but how confidently the material's identity and purity can be verified before it enters any protocol.
Growth Hormone Signalling Compounds
GHRPs And Ghrelin-Linked Research
Growth hormone releasing peptides (GHRPs) fall into two broad subgroups. The first includes ghrelin agonists such as ipamorelin and ibutamoren (MK-677). Ghrelin itself was actually discovered after researchers identified that synthetic agonists could bind a G protein-coupled receptor in the pituitary and stimulate pulsatile growth hormone release. Scientists then searched for the endogenous ligand and found ghrelin.
In research contexts, ghrelin agonists are studied in relation to borderline growth hormone deficiency and visceral lipodystrophy. MK-677 is one of the few orally bioavailable compounds in this class, which partly explains its popularity in research literature. It also partly explains its risk profile: published case reports describe reversible hyperglycaemia resembling gestational diabetes, driven by growth hormone's insulin-antagonistic effects rather than by increased food intake alone.
GHRH Analogues And IGF-1 Pathways
The second subgroup comprises GHRH analogues, including tesamorelin (Egrifta), CJC-1295, and sermorelin. These act on a different pituitary receptor from ghrelin agonists. Tesamorelin now holds FDA approval for multiple indications, making it the most clinically validated compound in this class.
One rationale for combining a low-dose ghrelin agonist with a low-dose GHRH analogue is synergy: each compound works through a separate receptor, so the combined effect may exceed what either achieves alone. This "one plus one equals three" concept allows lower individual doses, which in turn reduces dose-dependent side effects such as anxiety and appetite stimulation.
Common Research Interest And Key Safety Flags
The primary research interest centres on IGF-1 modulation. Dr Gillette suggests an IGF-1 range of roughly 100 to 250 ng/mL as a reference window, high enough to support lean tissue and metabolic function, low enough to avoid tumour-promotion risk and insulin resistance.
Key safety flags across both subgroups:
- Tumour growth: active benign or malignant tumours are a clear contraindication
- Hyperglycaemia: particularly documented with MK-677
- Anxiety and excessive sleepiness: reported with ghrelin agonists at higher doses
CJC-1295 merits a specific note. A clinical trial in Brazil was halted following a participant death. Many practitioners still favour CJC-1295, but that trial history is worth factoring into any risk-benefit assessment.
Repair, Angiogenesis And Tissue Support
BPC-157 And VEGF-Related Interest
BPC-157, or body protective compound 157, is the only peptide we are aware of that acts as a direct angiogenic agent through VEGF (vascular endothelial growth factor) pathways. Produced at higher levels endogenously in individuals with healthy gut mucosa, BPC-157 promotes capillary permeability and plasma leakage to injury sites, much like the body's own platelet-rich plasma response.
In practice, we have seen strong anecdotal results with BPC-157 for shoulder tendons, knee tendons, and meniscus-related complaints. Subcutaneous administration two to three times per week for two to six weeks is a common research and clinical protocol. If no observable effect appears within two to four weeks, the compound is unlikely to produce meaningful results for that particular tissue.
The major safety concern mirrors the GHRP class: tumour vascularisation. The chemotherapy drug bevacizumab (Avastin) works by blocking VEGF. Cancers tend to overexpress VEGF to fuel their own blood supply, so adding an angiogenic compound in that context would be counterproductive and potentially dangerous.
TB-500 And Broader Recovery Research
TB-500 is a synthetic fragment of thymosin beta-4, a protein produced by the thymus gland. Children, who still have an active thymus, tend to heal quickly; older adults, whose thymus has involuted, do not. TB-500 research attempts to recapture some of that regenerative capacity in a more targeted way than systemic growth hormone elevation.
TB-500 is frequently paired with BPC-157 in research protocols. Short courses are preferable to continuous use; the data supporting long-term thymus-related peptide use for immune enhancement, including thymosin alpha-1, is not compelling enough to justify the risk profile.
GHK-Cu And Regenerative Signalling
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) originates from the liver. Like thymosin beta-4, its endogenous levels are higher in younger individuals with well-functioning hepatic tissue. Copper itself is a trace element involved in red and white blood cell production.
A practical research consideration: individuals with impaired copper absorption, such as those who have undergone bariatric surgery, may present with deficient copper levels years after the procedure. Board-certified obesity medicine physicians routinely screen for this. In research settings, GHK-Cu offers a route to study copper-dependent regenerative signalling without systemic growth hormone elevation.
All three compounds in this class, BPC-157, TB-500, and GHK-Cu, are used off-label only. None has completed all three stages of clinical trials for an approved indication. That places additional weight on sourcing quality: identity testing and purity verification are non-negotiable when working with compounds that lack full regulatory validation.
Melanocortin And Amylin Pathways
Melanotan Compounds And PT-141
The melanocortin receptor agonists include four generations of compound:
| Compound | Also Known As | Primary Research Interest |
|---|---|---|
| Melanotan I (MT-1) | Afamelanotide | Photoprotection, tanning response |
| Melanotan II (MT-2) | — | Tanning, libido, appetite modulation |
| MT-3 / Bremelanotide | PT-141, Vyleesi | Hypoactive sexual desire disorder |
| MT-4 / Setmelanotide | Imcivree | Genetic obesity (leptin pathway defects, Bardet-Biedl syndrome) |
These compounds work through the limbic system, specifically the hypothalamus, amygdala, and hippocampus, where alpha-melanocyte-stimulating hormone (α-MSH) normally binds melanocortin receptors. Sunlight exposure triggers endogenous α-MSH release, which partly explains the well-documented link between sun exposure and increased libido.
PT-141 (bremelanotide/Vyleesi) holds an approved indication for hypoactive sexual desire disorder in females, though its mechanism acts on both sexes. It has a fast half-life and, when administered by injection, produces noticeable effects within minutes. Troche (buccal) formulations also exist, absorbed through the oral mucosa to bypass first-pass liver metabolism.
Pramlintide And Metabolic Research
Amylin is a peptide co-secreted with insulin by the pancreatic beta cells. Its synthetic analogue, pramlintide (Symlin), is indicated in diabetes and is markedly weight-negative. The challenge is adherence: pramlintide requires three daily injections due to its short half-life.
The next frontier involves long-acting amylin analogues designed for once-weekly dosing, potentially stacked with GLP-1 receptor agonists like semaglutide or tirzepatide. The research rationale is straightforward. In type 1 or advanced type 2 diabetes, beta cell function deteriorates. Replacing both insulin and amylin more closely replicates natural beta cell output and may reduce the weight gain commonly associated with insulin therapy alone.
A useful diagnostic marker: the pro-insulin to insulin ratio. When pro-insulin is disproportionately high relative to insulin, it signals impending beta cell failure. Amylin analogue research is particularly relevant in that subgroup.
Notable Adverse Effect Considerations
Across the melanocortin class, common adverse effects include:
- Nausea (reported across all four generations)
- Skin darkening (increased melanin deposition, even with later-generation compounds)
- Loss of photo-bleaching in hair (particularly noticeable in fair or dirty-blonde hair)
The theoretical concern with melanocortin agonists is melanoma promotion. Cancers that respond to α-MSH signalling could, in principle, be stimulated. Dr Gillette notes that medical science liaisons for the branded products report no melanoma cases in any clinical trial stage. Caution remains warranted for individuals with a family history of melanoma, red hair and pale skin (high-risk dermatotypes), or a history of multiple severe sunburns.
For amylin analogues, the primary adverse effect consideration is hypoglycaemia when combined with insulin, plus the practical burden of frequent dosing with current short-acting formulations.
Where SARMs Fit Into The Wider Landscape
What Selective Androgen Receptor Modulators Are
SARMs, or selective androgen receptor modulators, are not peptides. They are small molecules that bind the androgen receptor with tissue-selective activity. The concept parallels SERMs (selective oestrogen receptor modulators) such as tamoxifen or clomiphene, which act differently depending on the tissue.
The appeal is selectivity: in theory, a SARM could promote lean tissue retention in muscle without driving the full spectrum of androgenic effects seen with testosterone or its derivatives. In practice, selectivity is relative, not absolute.
Examples Such As RAD-140, LGD-4033 And MK-2866
Three compounds dominate the current research landscape:
- Ostarine (MK-2866 / Enobosarm): the furthest along in clinical development, now being studied for androgen-receptor-positive, triple-negative breast cancer and potentially prostate cancer applications
- Ligandrol (LGD-4033): studied for muscle wasting; notable for profoundly suppressing SHBG, sometimes to levels as low as 2 or 3 nmol/L
- RAD-140 (Testolone): similar SHBG suppression and androgen-receptor binding profile
When SHBG drops that low, hormonal metabolism loses its regulatory buffer. Free androgen levels rise disproportionately relative to free oestrogens, HDL cholesterol drops, and the liver's own androgen receptor activation contributes to further SHBG suppression. This creates a feedback loop that is well documented in research and should not be underestimated.
All SARMs cause some degree of hypothalamic-pituitary suppression. The claim that SARMs produce "no shutdown" is incorrect, just as the same claim about oxandrolone (Anavar) is incorrect. The suppression may be less dramatic than with injectable androgens, but it is measurable and clinically relevant.
Why SARMs Should Not Be Confused With Peptides
Peptides and SARMs share shelf space in many supplier catalogues, but they differ fundamentally in structure, mechanism, and regulatory status. Peptides are amino acid chains acting on specific receptor systems (GHS-R, MC4R, GLP-1R, and so on). SARMs are synthetic small molecules acting on the androgen receptor.
The distinction matters for research buyers because:
- Analytical verification methods differ (peptide identity testing relies heavily on mass spectrometry and HPLC; SARM verification may also require NMR)
- Storage and stability profiles differ
- Regulatory classification differs across jurisdictions
Grouping them together without acknowledging these differences leads to sloppy sourcing decisions and unreliable research outcomes.
Choosing A Credible UK Research Supplier
Why CoAs, HPLC And Mass Spec Matter
A Certificate of Analysis (CoA) is only as useful as the data it contains. For research-grade peptides and SARMs, the minimum standard includes:
- HPLC chromatograms confirming purity, typically above 98% for serious research use
- Mass spectrometry data confirming molecular identity
- Batch-matched documentation, meaning the CoA corresponds to the specific batch being dispatched, not a generic reference lot
Without batch-matched CoAs, there is no way to verify that the compound in the vial is the compound described on the label. This is not a theoretical concern. Independent analyses have repeatedly found mislabelled or underdosed products in the grey market.
Handling, Storage And Cold-Chain Standards
Many peptides are inherently unstable once reconstituted. Lyophilised (freeze-dried) formats offer better shelf stability, but even these require controlled storage conditions, typically between 2 and 8°C for short-term holding and below minus 20°C for long-term storage.
A credible supplier maintains cold-chain integrity from warehouse to dispatch. Domestic UK shipping reduces transit time and temperature exposure compared to international routes. For compounds like BPC-157 or GHK-Cu, which may degrade if exposed to heat or moisture during transit, this is a meaningful quality variable.
Why Buy Peptides UK Appeals To British Research Buyers
Buy Peptides UK supplies HPLC-verified, batch-tested research peptides and SARMs with batch-matched CoAs and mass spectrometry verification as standard. All orders are dispatched from within the UK, which shortens delivery windows and reduces cold-chain risk.
For institutional or bulk enquiries, dedicated support is available. The catalogue covers the major classes discussed in this guide, from GHRH analogues and BPC-157 through to melanocortin compounds and SARMs like MK-2866 and RAD-140.
Serious research demands serious sourcing. When the compound's identity and purity are confirmed before it enters a protocol, every downstream result carries more weight. That principle holds whether the study involves growth hormone signalling, tissue repair pathways, or androgen receptor selectivity.